Ultrastructural localization of cannabinoid CB1 and mGluR5 receptors in the prefrontal cortex and amygdala.
RRID:AB_2295173
RRID:RGD_10395233
electron microscopy
endocannabinoids
glutamate
heterosynaptic plasticity
prelimbic
Journal
The Journal of comparative neurology
ISSN: 1096-9861
Titre abrégé: J Comp Neurol
Pays: United States
ID NLM: 0406041
Informations de publication
Date de publication:
01 11 2019
01 11 2019
Historique:
received:
06
12
2018
revised:
01
04
2019
accepted:
17
04
2019
pubmed:
23
4
2019
medline:
20
9
2020
entrez:
23
4
2019
Statut:
ppublish
Résumé
Stimulation of the postsynaptic metabotropic glutamate receptor mGluR5 triggers retrograde signaling of endocannabinoids that activate presynaptic cannabinoid CB1 receptors on juxtaposing axon terminals. To better understand the synaptic structure that supports mGluR5 mediation of CB1 activation in the prefrontal cortex (PFC) and basolateral amygdala (BLA), we examined electron microscopic dual immunolabeling of these receptors in the prelimbic PFC (prPFC) and BLA of adult male rats. CB1 immunoreactivity was detected in axon terminals that were typically large, complex, and contained dense-core and clear synaptic vesicles. Of terminals forming discernible synaptic specializations, 95% were symmetric inhibitory-type in the prPFC and 90% were inhibitory in the BLA. CB1-immunoreactive terminals frequently contacted dendrites containing mGluR5 adjacent to unlabeled terminals forming excitatory-type synapses. Because most CB1-containing terminals form inhibitory-type synapses, the unlabeled axon terminals forming asymmetric synapses are the likely source of the mGluR5 ligand glutamate. In the prPFC, serial section analysis revealed that GABAergic CB1-containing axon terminals targeted dendrites adjacent to glutamatergic axon terminals, often near dendritic bifurcations. These observations provide ultrastructural evidence that cortical CB1 receptors are strategically positioned for integration of synaptic signaling in response to stimulation of postsynaptic mGluR5 receptors and facilitation of heterosynaptic communication between multiple neurons.
Identifiants
pubmed: 31008528
doi: 10.1002/cne.24704
pmc: PMC6722004
mid: NIHMS1527460
doi:
Substances chimiques
Cnr1 protein, rat
0
Grm5 protein, rat
0
Receptor, Cannabinoid, CB1
0
Receptor, Metabotropic Glutamate 5
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2730-2741Subventions
Organisme : NIMH NIH HHS
ID : T32 MH015144
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA007274
Pays : United States
Organisme : NIDA NIH HHS
ID : K05 DA021696
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA042943
Pays : United States
Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Eur J Neurosci. 1999 Dec;11(12):4213-25
pubmed: 10594647
J Neurosci. 2001 Feb 1;21(3):823-33
pubmed: 11157068
Nature. 2001 Mar 29;410(6828):588-92
pubmed: 11279497
Neuron. 2001 Aug 16;31(3):463-75
pubmed: 11516402
J Neurosci. 2001 Dec 1;21(23):9506-18
pubmed: 11717385
Neuroscience. 2001;107(4):641-52
pubmed: 11720787
J Neurosci. 2001 Dec 15;21(24):RC188
pubmed: 11734603
Nat Neurosci. 2002 Aug;5(8):723-4
pubmed: 12080342
Learn Mem. 2003 Mar-Apr;10(2):116-28
pubmed: 12663750
J Biol Chem. 2003 Jul 25;278(30):27742-9
pubmed: 12740378
Neuron. 2003 May 8;38(3):461-72
pubmed: 12741992
Science. 1992 Dec 18;258(5090):1946-9
pubmed: 1470919
J Comp Neurol. 2004 Jul 5;474(4):589-602
pubmed: 15174075
Neuroscience. 2004;127(1):101-12
pubmed: 15219673
Pharmacol Ther. 2004 Nov;104(2):117-35
pubmed: 15518883
J Neurosci. 2005 Jun 29;25(26):6199-207
pubmed: 15987949
J Neurosci. 2005 Jul 20;25(29):6845-56
pubmed: 16033894
J Neurosci. 2006 May 24;26(21):5628-37
pubmed: 16723519
J Neurophysiol. 2007 Apr;97(4):2580-9
pubmed: 17267760
Neuroscience. 2007 Jun 8;146(4):1536-45
pubmed: 17467187
Science. 2007 May 25;316(5828):1212-6
pubmed: 17525344
PLoS One. 2007 Aug 08;2(8):e709
pubmed: 17684555
Handb Exp Pharmacol. 2008;(184):435-77
pubmed: 18064422
J Neurosci. 2008 Dec 3;28(49):13028-37
pubmed: 19052194
J Neurosci. 1991 Feb;11(2):563-83
pubmed: 1992016
Folia Biol (Praha). 2009;55(6):201-17
pubmed: 20163769
J Neurosci. 2010 Apr 14;30(15):5451-64
pubmed: 20392966
Synapse. 2011 Apr;65(4):278-86
pubmed: 20687106
Cereb Cortex. 2011 Sep;21(9):2056-64
pubmed: 21263035
Neuropharmacology. 2012 Mar;62(3):1461-72
pubmed: 21620876
J Neurosci. 2011 Jul 20;31(29):10506-15
pubmed: 21775596
Psychopharmacology (Berl). 2012 May;221(1):101-13
pubmed: 22160162
J Cell Biol. 2012 Apr 16;197(2):327-37
pubmed: 22492722
Neuropharmacology. 2013 Mar;66:170-8
pubmed: 22521499
J Comp Neurol. 2012 Dec 1;520(17):4013-31
pubmed: 22592925
Neurosci Lett. 2012 Aug 22;524(1):65-8
pubmed: 22819970
Biochem Biophys Res Commun. 2012 Oct 12;427(1):185-90
pubmed: 22995293
J Neurochem. 2013 Mar;124(6):795-807
pubmed: 23289830
Neuroscience. 2013 Apr 3;235:40-50
pubmed: 23333674
J Neurosci. 2013 Jan 30;33(5):2156-65
pubmed: 23365251
Eur J Neurosci. 2014 Feb;39(3):455-66
pubmed: 24494685
J Neurosci. 2015 Mar 4;35(9):3842-50
pubmed: 25740514
J Neurosci. 2015 Mar 11;35(10):4215-28
pubmed: 25762668
Neuroscience. 2016 May 26;323:35-42
pubmed: 25967266
Front Neuroanat. 2016 Mar 07;10:20
pubmed: 27013983
J Biol Chem. 2017 Mar 3;292(9):3637-3655
pubmed: 28096465
Adv Pharmacol. 2017;80:169-206
pubmed: 28826534
Neurosci Lett. 1996 Jan 26;203(3):211-3
pubmed: 8742030
Nature. 1997 Aug 21;388(6644):773-8
pubmed: 9285589